SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer SS Innovations International, Inc. appoints seasoned executive Milan Rao to drive global growth, operational scale, and expanded access to affordable robotic surgery.Fort Lauderdale, FL, January 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technolog ...

FORT LAUDERDALE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Milan Rao as the Company’s Global Chief Operating Officer and Chief Financial Officer. The Global Chief Operating Officer role is a newly created position. Mr. Rao will succeed Naveen Kumar A ...

Smaller 5-millimeter instruments to be incorporated into the SSi Mantra surgical robotic systemFORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has completed the development of five new 5-millimeter surgical instruments for clinical use acros ...

Core Viewpoint - SS Innovations has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple surgical specialties and aiming for U.S. market entry [1][3][5] Company Overview - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [8] - The company is headquartered in India and plans to expand its global presence with cost-effective surgical robotic solutions [8] Product Details - The SSi Mantra surgical robotic system supports various surgical specialties, including general, urological, colorectal, gynecological, and cardiac procedures [2][3] - The system features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, a large 3D 4K monitor, and over 40 types of robotic endo-surgical instruments [10] Regulatory Progress - The 510(k) submission is part of the company's strategic plan to introduce the SSi Mantra system to the U.S. market, with the expectation of a review completion within 90 days, although actual approval may take longer [6] - The company is also pursuing EU CE Mark approval, which it anticipates could be obtained in the first half of 2026 [6] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system and over 7,300 surgical procedures performed [6]

Core Viewpoint - SS Innovations International, Inc. has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, aiming to enhance accessibility and affordability of robotic surgery in the U.S. market [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery accessible to a broader global population [5] - The company is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] Product Details - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities [6] - It has been clinically validated in India for over 100 different types of surgical procedures [6] Regulatory Progress - The FDA aims to complete reviews of 510(k) submissions within 90 days, although actual approval times may vary [3] - The company is also pursuing CE marking certification in the European Union, expected in the first half of 2026 [3] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system [4] - Over 7,300 surgical procedures have been performed using the SSi Mantra, including 88 telesurgeries and 390 cardiac procedures [4]

Core Insights - The recent market correction has created buying opportunities for investors in high-growth companies that are addressing real-world problems, with many stocks trading at 30-day lows despite strong operational progress [1][2]. Group 1: Symbotic (SYM) - Symbotic develops AI-enabled robotic systems for automating high-volume warehouses, reporting Q3 2025 revenue of $592 million, a 26% year-over-year increase, and adjusted EBITDA rising to $45 million from $3 million [3][5]. - The company has a significant backlog of approximately $22.4 billion, primarily from long-term contracts with Walmart and GreenBox, providing multiyear revenue visibility [5][6]. - Despite a 14% decline in shares over the past 30 days, the company is positioned for growth with a substantial contracted workload ahead [6]. Group 2: AST SpaceMobile (ASTS) - AST SpaceMobile aims to create the first space-based cellular broadband network compatible with standard smartphones, achieving Q3 2025 revenue of $14.7 million, up from $1.1 million a year ago, driven by government contracts [7][9]. - The company has over $1 billion in contracted revenue commitments and has signed agreements with more than 50 mobile network operators, serving nearly 3 billion subscribers [9][10]. - Execution and launch timelines are critical factors, with recent revenue misses contributing to stock volatility, but the current weakness offers a favorable entry point for investors [10]. Group 3: SS Innovations International (SSII) - SS Innovations has installed over 100 SSi Mantra surgical robotic systems and completed over 5,000 procedures, indicating a transition from concept to scale [11][13]. - The company plans to file a 510(k) premarket notification in Q4 2025 for multiple surgical indications, which could expedite FDA clearance [13][14]. - This small-cap stock has shown less volatility compared to others, with only a 5% decline over the past 30 days as investors await regulatory updates [15].

Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Core Insights - SS Innovations International, Inc. has successfully completed its first telesurgery using the SSi Mantra Tele Surgeon Console (TSC), demonstrating the console's capability to facilitate surgeries from various locations, including physician offices [1][2][3] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [4] Product Details - The SSi Mantra Tele Surgeon Console is a compact, self-contained chair-based system that allows for telesurgeries without the need for a full operating room [1][3] - The TSC features inbuilt electronics, lightweight glasses, a magnified 3D view, and magnetic sensor-based controls, making it suitable for remote surgical procedures [3] - The SSi Mantra surgical robotic system includes modular robotic arms, a 3D 4K monitor, and supports over 40 types of robotic endo-surgical instruments for various specialties, including cardiac surgery [5]

Revenue Growth - Revenue increased 192.5% year over year to $12.8 million from $4.4 million in Q3 2024[5] - Total revenue for the first nine months of 2025 increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024[5] - Total revenue for Q3 2025 reached $12,829,349, a significant increase of 192% compared to $4,386,516 in Q3 2024[20] - For the nine months ended September 30, 2025, total revenue was $27,950,264, an increase of 123% from $12,533,335 in the same period of 2024[21] Gross Profit and Margin - Gross profit rose 166.0% to $6.2 million from $2.3 million in Q3 2024[5] - Gross profit for Q3 2025 was $6,164,936, compared to $2,317,407 in Q3 2024, reflecting a gross margin improvement[20] System Installations and Surgeries - SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in Q3 2024[5] - SSi Mantra installations for the first nine months of 2025 totaled 63, up 152.0% from 25 installations in the first nine months of 2024[10] - Cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures[5] Net Loss and Financial Performance - Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in Q3 2024[5] - The net loss for Q3 2025 was $3,717,964, compared to a net loss of $3,245,483 in Q3 2024, indicating a worsening of financial performance despite revenue growth[20] Cash and Liquidity - Cash and cash equivalents totaled $5.7 million, excluding restricted cash[5] - Cash and cash equivalents at the end of Q3 2025 were $12,039,247, up from $6,152,262 at the end of Q3 2024, showing improved liquidity[23] Operating and Research Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $20,626,239, slightly down from $21,620,651 in the same period of 2024[21] - Research and development expenses for the nine months ended September 30, 2025, were $2,295,014, an increase from $1,729,834 in the same period of 2024[21] Foreign Currency Impact - The company reported a foreign currency translation loss of $480,822 in Q3 2025, compared to a loss of $59,087 in Q3 2024[20] Future Plans - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025[6] - The company aims for European Union CE marking certification in the first half of 2026[6] Share Dilution - The weighted average diluted shares increased to 202,856,501 in Q3 2025 from 181,885,269 in Q3 2024, reflecting dilution from equity financing[20]

Financial Performance - Total revenue for the three months ended September 30, 2025, was $12,829,349, a significant increase from $4,386,516 for the same period in 2024, representing a growth of approximately 192%[202]. - Gross profit for the three months ended September 30, 2025, was $6,164,936, compared to $2,317,407 in the same period of 2024, reflecting an increase in gross profit margin due to lower raw material prices[203]. - For the nine months ended September 30, 2025, total revenue was $27,950,264, compared to $12,533,335 for the same period in 2024, marking an increase of approximately 123%[212]. - The net loss for the three months ended September 30, 2025, was $3,717,964, compared to a net loss of $3,245,483 for the same period in 2024, despite an increase in gross profit[211]. - The Company reported a net loss of $17,227,806 for the nine months ended September 30, 2024, with non-cash adjustments of $13,528,234[232]. Market Activity - The company sold 28 surgical robotic systems in the three months ended September 30, 2025, and 55 systems in the nine months ended September 30, 2025, indicating a growing market presence[197]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $786,319, up from $442,839 in the same period of 2024, reflecting ongoing investment in product enhancements[204]. - Selling, general and administrative expenses increased to $4,821,552 for the three months ended September 30, 2025, compared to $2,508,479 in the same period of 2024, primarily due to higher legal and underwriting fees[207]. Assets and Cash Flow - Total assets as of September 30, 2025, were $69,577,027, up from $42,385,213 as of December 31, 2024, indicating strong growth in the company's financial position[200]. - Cash at the end of the year on September 30, 2025, was $12,039,247, compared to $6,152,262 at the end of the previous year[230]. - In the nine months ended September 30, 2025, the net cash used in operating activities was $17,023,417, resulting from a net loss of $9,656,008[230]. - The Company had a net cash used in investing activities of $1,944,527 for the purchase of property and equipment during the nine months ended September 30, 2025[234]. Financing Activities - The Company raised $24,793,391 from financing activities during the nine months ended September 30, 2025, primarily from the issuance of convertible notes[235]. - The Company sold $2,450,000 in principal amount of 7% Convertible One-Year Promissory Notes, with a conversion price of $4.45 per share[225]. - As of September 30, 2025, all $30,000,000 in principal amount of One-Year Notes were converted into 21,858,368 shares of common stock at a conversion price of $1.38 per share[228]. - The net cash provided by financing activities in the nine months ended September 30, 2024, was $6,014,946, including proceeds from convertible notes and promissory notes[236]. - The Company raised $2,000,000 from Sushruta through the issuance of two One-Year 7% Promissory Notes in April 2024[226]. Taxation and Funding Concerns - The company incurred an income tax expense of $1,847,059 for the three months ended September 30, 2025, due to the recognition of taxable profits in its Indian operations for the first time[210]. - The Company does not have any committed sources of funding, raising substantial doubt about its ability to continue as a going concern[229]. - The Company plans to raise additional capital through private or public offerings to support its expansion and R&D efforts, highlighting the need for ongoing funding[201].